K-Drops (Ketotifen Hydrogen Fumarate)

Ketotifen hydrogen fumarate blocks H1 histamine receptors on conjunctival cells and stabilises mast cells, preventing the release of histamine, leukotrienes and other inflammatory mediators. This dual action reduces vascular leakage, swelling and nerve activation, thereby alleviating itching, redness and swelling in the eye.

The dosing regimen for K-Drops is determined by the prescribing healthcare professional based on the severity of the allergic eye condition and patient response. Typically, one to two drops are instilled in the affected eye(s) as directed, but the exact frequency and duration should follow the prescriber’s instructions.

Safety data for ketotifen hydrogen fumarate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To request K-Drops, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team will then provide pricing, availability, shipping details and any required import documentation.

K-Drops (ketotifen) combines H1‑receptor antagonism with mast‑cell stabilisation, offering both immediate symptom relief and longer‑term control of allergic inflammation. Other ocular antihistamines may provide only H1 blockade without stabilising mast cells, potentially requiring more frequent dosing for comparable effect.

K-Drops should be stored at room temperature, below 25 °C, in the original packaging. Keep the bottle tightly closed, protect it from direct light and moisture, and discard any product that appears discoloured or has particles after the expiry date.

K-Drops is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively to allow absorption.

Serious but rare risks include severe allergic reactions such as angio‑edema of the eyelid, corneal ulceration, persistent eye pain, significant visual changes, or secondary ocular infection. Any sudden worsening of eye symptoms should prompt immediate medical evaluation.

K-Drops should be avoided in individuals with known hypersensitivity to ketotifen hydrogen fumarate or any of the formulation excipients. Patients with active ocular infections, uncontrolled glaucoma, or those who have had a severe reaction to similar ophthalmic antihistamines should also refrain from use unless advised otherwise by a clinician.